Treatment of Obesity with Tirzepatide

Patient Selection and Initiation

The American Diabetes Association recommends initiating tirzepatide for patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea 1, 2
Patients should be screened for absolute contraindications, including personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2) 1, 2, 3
Assess for history of pancreatitis and use with caution if present, though causality with tirzepatide has not been definitively established 1, 2

Start tirzepatide at 5 mg subcutaneously once weekly, with gradual dose escalation every 4 weeks to minimize gastrointestinal symptoms 2, 3
Advance doses every 4 weeks based on gastrointestinal tolerance and weight loss response, with a maximum dose of 15 mg weekly 2, 3

The American Heart Association recommends a caloric deficit of 500-kcal reduction below daily requirements, combined with at least 150 minutes per week of moderate-intensity exercise and resistance training to preserve lean body mass during weight loss 1, 2, 3
Behavioral therapy, including structured lifestyle management programs and behavioral counseling, is essential for long-term weight loss maintenance 2, 3

Assess patients monthly during the first 3 months for efficacy and safety, and every 3 months thereafter, monitoring weight loss progress, blood pressure, and gastrointestinal tolerance 1, 2
Discontinue tirzepatide if less than 5% weight loss is achieved after 12 weeks at maintenance dose, as this predicts poor long-term response 2, 3

Patients can expect 15-21% weight loss with tirzepatide at higher doses over 72 weeks, with approximately 50-57% achieving ≥20% weight reduction 2, 3
Additional cardiometabolic benefits include blood pressure reduction, superior triglyceride reduction, and improved lipid profiles 2, 3

Gastrointestinal effects, such as nausea, diarrhea, and vomiting, are the most common adverse events, occurring primarily during dose escalation and typically mild-to-moderate in severity 1, 2, 3
Mitigation strategies include slow titration, dietary modifications, and reassurance that gastrointestinal symptoms typically decrease over time with continued exposure 2, 3

Prioritize tirzepatide for patients with type 2 diabetes and obesity due to dual benefits of glycemic control and superior weight loss 1, 2
No dose adjustment is required for tirzepatide in patients with chronic kidney disease, including those with eGFR <30 mL/min/1.73 m² 2, 3